ReviewNature reviews. Rheumatology2020
Views on glucocorticoid therapy in rheumatology: the age of convergence.
Review in Nature reviews. Rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02719314 (Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids), which is not on this map. Cited by 57 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Non-interventional Clinical Trial to Establish a Glucocorticoid-induced Osteoporosis Databank for Patients With Chronic Inflammatory Rheumatic Diseases or Psoriasis and Therapy With Glucocorticoids
Who cites it
57 citing papers in PubMed, 4 syntheses or guidelines pooled it, 113 citations in OpenAlex.
- Guideline
- Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.Frontiers in immunology · 2023Pooled it
- The effect of disease-modifying anti-rheumatic drugs on skeletal muscle mass in rheumatoid arthritis patients: a systematic review with meta-analysis.Arthritis research & therapy · 2022Pooled it
- The prevalence and impact of depression in primary systemic vasculitis: a systematic review and meta-analysis.Rheumatology international · 2020Pooled it
- Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study.Rheumatology and therapy · 2026Article
- Development and validation of a risk score for serious infection in patients with rheumatic diseases receiving prolonged high-dose glucocorticoids.Arthritis research & therapy · 2026Article
- The N-butanol extract of modified Yanghe decoction alleviates ferroptosis in bone marrow mesenchymal stem cells in glucocorticoid-induced osteoporosis by activating the HIF-1α/GPX4 signaling pathway.Journal of orthopaedic surgery and research · 2025Article
- Anti-Cancer Outcome of Glucocorticoid Receptor Transrepression by Synephrine Derivatives in Hematological Malignancies.International journal of molecular sciences · 2025Article
- Visualizing Real-World Pain Treatment Pathways in Chronic Disease: A Sequence-Based Analysis of Polypharmacy in Systemic Lupus Erythematosus.ACR open rheumatology · 2025Article
- Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids.Rheumatology and therapy · 2025Article
- Obesity: pathophysiology and therapeutic interventions.Molecular biomedicine · 2025Review
- Review
- Innovative nanocarriers in arthritis therapy: the role of herbal cubosomes.Inflammopharmacology · 2025Review
- Association of Rheumatoid Arthritis With Progression of Cognitive Impairment and Risk of Mortality in People With Dementia.Neurology · 2025Article
- Novel selective glucocorticoid receptor modulator GRM-01 demonstrates dissociation of anti-inflammatory effects from adverse effects on glucose and bone metabolism.Frontiers in pharmacology · 2025Article
- Tau is a receptor with low affinity for glucocorticoids and is required for glucocorticoid-induced bone loss.Cell research · 2025Article
- Glucocorticoid use and perceptions of side effects among patients with rheumatic medical diseases: Insights from a developing country.PloS one · 2025Article
- Negative association between serum calcium and glucocorticoid-induced hypertension in thyroid-associated ophthalmopathy patients treated with methylprednisolone.Frontiers in endocrinology · 2025Article
- Data mining historical Chinese medical recipe collections and nuclear receptor profiling identify plant fractions that modulate glucocorticoid receptor activity.Frontiers in pharmacology · 2025Article
- Rheumatic diseases and metabolism: where centre and periphery meet.Nature reviews. Rheumatology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After decades of sometimes fierce debate about the advantages and disadvantages of glucocorticoids, an age of convergence has been reached. Current recommendations for the management of diseases such as rheumatoid arthritis (RA), polymyalgia rheumatica and large vessel vasculitis reflect the current consensus that as much glucocorticoid as necessary, but as little as possible, should be used. Over the past few years, a range of glucocorticoid-sparing strategies have been developed, as have tools to improve the management of this therapy. A comprehensive view of glucocorticoid-induced osteoporosis has also emerged that recognizes that bone fragility is not solely determined by the dose and duration of glucocorticoid treatment. Nevertheless, open questions remain around whether long-term use of very low doses of glucocorticoids is a realistic option for patients with RA and whether the search for innovative glucocorticoids or glucocorticoid receptor ligands with improved benefit-to-risk ratios will ultimately be successful.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.